Janice Suzann Drew Sells 20,000 Shares of Evommune (NYSE:EVMN) Stock

Evommune, Inc. (NYSE:EVMN) insider Janice Suzann Drew sold 20,000 shares of the business’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $22.63, for a total transaction of $452,600.00. Following the sale, the insider directly owned 67,794 shares in the company, valued at approximately $1,534,178.22. This represents a 22.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Evommune Trading Down 3.0%

EVMN traded down $0.72 on Wednesday, hitting $23.53. 1,043,288 shares of the company were exchanged, compared to its average volume of 453,427. Evommune, Inc. has a fifty-two week low of $13.89 and a fifty-two week high of $33.20. The business’s fifty day moving average is $23.14 and its 200 day moving average is $22.27.

Evommune (NYSE:EVMN) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.19. On average, research analysts predict that Evommune, Inc. will post -2.85 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

EVMN has been the topic of several research reports. Morgan Stanley upped their target price on Evommune from $54.00 to $55.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Wall Street Zen downgraded Evommune from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Clear Str raised shares of Evommune to a “strong-buy” rating in a research note on Tuesday, March 17th. Royal Bank Of Canada restated an “outperform” rating and set a $48.00 target price on shares of Evommune in a report on Friday, April 10th. Finally, Oppenheimer assumed coverage on shares of Evommune in a research report on Tuesday, April 7th. They set an “outperform” rating and a $50.00 target price for the company. Three analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $49.25.

Institutional Trading of Evommune

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Capricorn Fund Managers Ltd purchased a new position in Evommune in the 4th quarter valued at about $1,027,000. NEXTBio Capital Management LP purchased a new stake in shares of Evommune during the fourth quarter worth about $3,908,000. Sofinnova Investments Inc. purchased a new stake in shares of Evommune during the fourth quarter worth about $2,625,000. Seven Grand Managers LLC acquired a new position in shares of Evommune in the fourth quarter valued at approximately $1,284,000. Finally, Monashee Investment Management LLC acquired a new position in shares of Evommune in the fourth quarter valued at approximately $3,137,000.

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.